Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Company remains on track to initiate the clinical trial in Q4 of 2023
ROCKVILLE, Md., Sept. 25, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage...

Related Keywords

Anatoly Dritschilo ,Robert Blum ,Ropidoxuridine Ipd ,Lytham Partners ,Company Chemistry ,Nasdaq ,Shuttle Pharmaceuticals Holdings Inc ,Shuttle Pharmaceuticals ,Georgetown University ,Drug Administration ,Prnewswire Shuttle Pharmaceuticals Holdings Inc ,Pharmaceuticals Holdings ,Investigational New Drug Application ,Shuttle Pharma ,Orphan Drug Designation ,Medical Center ,Annual Report ,Quarterly Reports ,Markets ,